Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo

https://doi.org/10.1016/0378-8741(94)01182-6Get rights and content

Abstract

(−)-Huperzine-A has been shown to be a promising agent for the treatment of dementia of the Alzheimer type. This substance is rare in nature. We have been able to prepare a racemic mixture of (±)-huperzine-A in quantity. In the absence of a chiral synthetic procedure for (−)-huperzine-A, this study sought to determine whether the racemic mixture would yield an in vitro and in vivo pharmacological profile of activity similar to that of the natural compound. The synthetic racemic mixture (±)-huperzine-A was 3 times less potent than (−)-huperzine-A in vitro (IC50s of 3 × 10−7 M and 10−7 M, respectively) because the former consisted of a racemic mixture of the compound in which the (+)-huperzine component was considerably less potent (IC50 = 7 × 10−6M). A comparable magnitude of effect was also observed in studies conducted in vivo, in which, over a range of 0.1–2.0 mg/kg administered intraperitoneally (i.p.), both (−)-huperzine-A and (±)-huperzine-A exerted significant inhibition of acetylcholinesterase activity, in all brain regions tested (hippocampus, striatum, hypothalamus and frontal cortex). This inhibition of acetylcholinesterase activity was inversely related to levels of acetylcholine measured in the hippocampus and followed the same time course of effect. (−)-Huperzine-A and (±)-huperzine-A were shown to be more potent than physostigmine as inhibitors of acetylcholinesterase in vitro (IC50 = 6 × 10−7M). Moreover, their inhibitory effect on acetylcholinesterase in vivo was of a longer duration (peak activity of 20 min for physostigmine versus 60 min for the huperzine variants), at the doses tested. Finally, no effect was exerted by either of the huperzine variants on choline acetyltransferase activity in cortex or hippocampus, over a wide range of doses tested (0.1–1.0 mg/kg, i.p.). These findings demonstrate that (±)- huperzine-A compares in its activity and biological effects with the natural product, (−)-huperzine-A, both in vitro and in vivo.

References (34)

  • F. Fonnum

    Topographical and subcellular localization of choline acetyltransferase in rat hippocampal regions

    Journal of Neurochemistry

    (1970)
  • S. Gauthier et al.

    Status of THA as therapy for Alzheimer's disease

  • J. Glowinski et al.

    Regional studies of catecholamines in the rat brain. I. The disposition of [3H]-norepinephrine, [3H]-dopamine and [3H]-DOPA in various regions of the brain

    Journal of Neurochemistry

    (1966)
  • I. Hanin et al.

    Clinical and preclinical studies with huperzine

  • I. Hanin et al.

    Synthetic analogs of huperzine-A (Hup-A): structural requirements for activity as an acetylcholinesterase inhibitor (AChEI) in vitro

    FASEB Journal

    (1991)
  • A.P. Kozikowski et al.

    Synthesis of huperzine-A and its analogues, and their anticholinesterase activity

    Journal of Organic Chemistry

    (1991)
  • R.E. McCaman et al.

    Microdetermination of choline acetylase in nerve tissue

    Journal of Neurochemistry

    (1965)
  • Cited by (0)

    View full text